Literature DB >> 3148604

Inhibitory effect of tamoxifen on diethylstilbestrol-promoted hepatic tumorigenesis in male rats and its possible mechanism of action.

K Kohigashi1, Y Fukuda, H Imura.   

Abstract

Male Sprague-Dawley rats were given a single intraperitoneal injection of diethylnitrosamine (DEN, 200 mg/kg body weight). Two weeks later the rats were divided into 4 groups; DEN-C group rats were given no further treatment; DEN-DES group rats were fed diethylstilbestrol (DES, 0.5 mg/day); DEN-TMX group rats were given tamoxifen (TMX, 1.0 mg/day) orally; DEN-DES TMX group rats were fed both DES and TMX for 8 months. Rats of the DEN-DES group developed grossly visible hepatic tumors. On the other hand, tumor development was significantly inhibited in rats of the DEN-DES TMX group. Total area of gamma-glutamyl transpeptidase-positive lesions and the mean area per lesion were significantly larger in rats of the DEN-DES group than those of the DEN-C, DEN-TMX or DEN-DES-TMX group. Estrogen receptor (ER) content of liver cytosol assayed by enzyme immunoassay (EIA) was significantly greater in rats of the DEN-DES group than in those of the DEN-C group and smaller in rats of the DEN-TMX and DEN-DES TMX group than in the DEN-C group. On the contrary, ER content of liver nuclei was significantly greater in rats of the DEN-TMX and DEN-DES TMX group than in those of the DEN-C or DEN-DES group. These results suggest that the promotive action of DES and the inhibitory action of TMX on DES-promoted hepatic tumorigenesis are, at least in part, mediated by ER in the rat.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3148604      PMCID: PMC5917654          DOI: 10.1111/j.1349-7006.1988.tb01564.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


diethylnitrosamine diethylstilbestrol tamoxifen estrogen receptor enzyme immunoassay ethylenediaminetetraacetate bovine serum albumin hematoxylin and eosin γ‐glutamyl transpeptidase
  20 in total

1.  Report of a workshop on classification of specific hepatocellular lesions in rats.

Authors:  R A Squire; M H Levitt
Journal:  Cancer Res       Date:  1975-11       Impact factor: 12.701

2.  Possible association between benign hepatomas and oral contraceptives.

Authors:  J K Baum; J J Bookstein; F Holtz; E W Klein
Journal:  Lancet       Date:  1973-10-27       Impact factor: 79.321

3.  Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells.

Authors:  W J King; G L Greene
Journal:  Nature       Date:  1984 Feb 23-29       Impact factor: 49.962

4.  Changes in estrogen receptor levels during DES-induced hepatocarcinogenesis in the Syrian hamster fed alpha-naphthoflavone.

Authors:  S A Li; J J Li
Journal:  J Steroid Biochem       Date:  1981-12       Impact factor: 4.292

5.  Estrogen receptor in rat liver and its dependence on prolactin.

Authors:  G C Chamness; M E Costlow; W L McGuire
Journal:  Steroids       Date:  1975-09       Impact factor: 2.668

6.  Role of estrogens as promoters of hepatic neoplasia.

Authors:  I R Wanless; A Medline
Journal:  Lab Invest       Date:  1982-03       Impact factor: 5.662

7.  Conditions for the measurement of nuclear estrogen receptor at low temperature.

Authors:  W C Okulicz; R A Boomsma; R G MacDonald; W W Leavitt
Journal:  Biochim Biophys Acta       Date:  1983-05-04

8.  Effects of ethinyl estradiol and tamoxifen on liver DNA turnover and new synthesis and appearance of gamma glutamyl transpeptidase-positive foci in female rats.

Authors:  J D Yager; B D Roebuck; T L Paluszcyk; V A Memoli
Journal:  Carcinogenesis       Date:  1986-12       Impact factor: 4.944

9.  Biological activities of tamoxifen aziridine, an antiestrogen-based affinity label for the estrogen receptor, in vivo and in vitro.

Authors:  L L Wei; W F Mangel; B S Katzenellenbogen
Journal:  J Steroid Biochem       Date:  1985-12       Impact factor: 4.292

10.  Hepatocellular carcinoma and oral contraceptives.

Authors:  B E Henderson; S Preston-Martin; H A Edmondson; R L Peters; M C Pike
Journal:  Br J Cancer       Date:  1983-09       Impact factor: 7.640

View more
  3 in total

Review 1.  Tamoxifen and secondary tumours. An update.

Authors:  N Wilking; E Isaksson; E von Schoultz
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

2.  Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats.

Authors:  Y P Dragan; S Fahey; K Street; J Vaughan; V C Jordan; H C Pitot
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 3.  Cellular origins of regenerating liver and hepatocellular carcinoma.

Authors:  Ágnes Holczbauer; Kirk J Wangensteen; Soona Shin
Journal:  JHEP Rep       Date:  2021-12-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.